The assessment of fibroblast growth factor 19 as a non-invasive serum marker for hepatocellular carcinoma
Hadeer Mohammed Fawzy;
Abstract
Liver cirrhosis represents the end stage of several chronic liver injuries. It is characterized by degeneration, regeneration by nodules with loss of lobular architecture, which results in decrease of liver cell mass, portal hypertension and porto-systemic shunt opening.
Hepatocellular carcinoma (HCC) represent the 5th common cancer worldwide and 3rd cause of death between cancers, which represent the most serious complication following chronic infection by hepatitis (C) virus and hepatitis (B) virus.
Tumor makers are widely used as a diagnostic follow up after treatment and prognosis. In HCC α fetoprotein (α FP) is used for diagnosis, follow up of HCC but with different variable changes so it cannot used alone as a biomarker of HCC.
Serum fibroblast growth factor 19 (FGF
Hepatocellular carcinoma (HCC) represent the 5th common cancer worldwide and 3rd cause of death between cancers, which represent the most serious complication following chronic infection by hepatitis (C) virus and hepatitis (B) virus.
Tumor makers are widely used as a diagnostic follow up after treatment and prognosis. In HCC α fetoprotein (α FP) is used for diagnosis, follow up of HCC but with different variable changes so it cannot used alone as a biomarker of HCC.
Serum fibroblast growth factor 19 (FGF
Other data
| Title | The assessment of fibroblast growth factor 19 as a non-invasive serum marker for hepatocellular carcinoma | Other Titles | تقييم عامل نمو الخلايا الليفية 19 كدلالة لسرطان الخلايا الكبدية | Authors | Hadeer Mohammed Fawzy | Issue Date | 2021 |
Attached Files
| File | Size | Format | |
|---|---|---|---|
| BB11780.pdf | 1.82 MB | Adobe PDF | View/Open |
Similar Items from Core Recommender Database
Items in Ain Shams Scholar are protected by copyright, with all rights reserved, unless otherwise indicated.